Jonathan Cebon

Program Head

Olivia Newton-John Cancer Research Institute

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Immunology Immunology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jonathan Cebon is the Program Head at the Olivia Newton-John Cancer Research Institute in Australia. His research focuses on advanced melanoma and the immunological responses related to cancer therapies, including the effects of PD-1 and CTLA-4 blockade. He has contributed significantly to studies on combination immunotherapy and predictive biomarkers in cancer treatment, particularly in relation to melanoma and malignant pleural mesothelioma.

Articles (10)

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (8)

Hilary Sheppard

Senior Lecturer

University of Auckland

NEW ZEALAND

View details

Jessica Da Gama Duarte

Laboratory Head/Senior Research Fellow

Monash University Malaysia.

AUSTRALIA

View details

Shengbo Zhang

Walter and Eliza Hall Institute of Medical Research

AUSTRALIA

View details

Nicolas Jacquelot

University of Calgary

CANADA

View details

Qiutong Huang

Walter and Eliza Hall Institute of Medical Research

AUSTRALIA

View details

Richard Kefford

Macquarie University

AUSTRALIA

View details

Daniel Gray

Joint Division Head and Laboratory Head

Walter and Eliza Hall Institute of Medical Research

AUSTRALIA

View details

Erinna Lee

La Trobe University

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jonathan Cebon

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma

A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma.

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules

<i>PDCD1</i> Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.

Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.

Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy.

Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538

Ropporin‐1 and 1b are widely expressed in human melanoma and evoke strong humoral immune responses

Long-term follow-up of standard-dose pembrolizumab plus reduced-dose ipilimumab in patients with advanced melanoma

Migratory cues controlling B-lymphocyte trafficking in human lymph nodes.

Collaborators (8)

Hilary Sheppard

Jessica Da Gama Duarte

Shengbo Zhang

Nicolas Jacquelot

Qiutong Huang

Richard Kefford

Daniel Gray

Erinna Lee

Make your next move.